Lewy body dementia
Therapeutic area
Metabolic Disease
Rare disease
Yes
- Definition
- A progressive form of dementia characterized by the presence of protein deposits called Lewy bodies in the midbrain and cerebral cortex, and loss of cholinergic and dopaminergic neurons. The signs and symptoms overlap with Alzheimer and Parkinson disease.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Lewy body dementia
- Therapeutic area
- Metabolic Disease
- Lewy body dementia
- DLB
- Lewy body dementia
- Lewy body disease
- cortical Lewy body disease
- dementia with Lewy bodies
- lewy body dementia, susceptibility to
- dementia, Lewy body
- Severity
- Severe
- Metabolic Disease
- Neurology
- MONDO ID
- MONDO:0007488
- Parent condition
- MONDO:0000510
Related records
Broader conditions (14)
- Central nervous system disorder
- Cognitive disorder
- Dementia
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by molecular mechanism
- Human disease
- Metabolic disease
- Nervous system disorder
- Neurodegenerative disease
- Proteostasis deficiencies
- Psychiatric disorder
- Synucleinopathy
Trials (232)
- "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
- [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
- [18F]ACI-15916 PET in α-synucleinopathies
- [18F]F-DOPA Imaging in Patients With Autonomic Failure
- 18F-DOPA II - PET Imaging Optimization
- 18F-mFBG Cardiac Uptake With Lewy Body Dementia
- 5-HT RBD REM Sleep Behavior Disorder
- A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
- A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
- A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
- A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
- A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
- A Phase I Study of GT300 in Healthy Subjects
- A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
- A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research
- A Study of Caregiver Connections Via Technology in Dementia
- A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
- A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
Approved drugs (1)
- Ioflupane I 123
Drugs in development (14)
- Ambroxol Phase 1
- Bosutinib Phase 2
- Fosgonimeton Phase 1
- Fosgonimeton sodium Phase 1
- Galantamine Phase 3
- Irsenontrine Phase 1
- Irsenontrine maleate Phase 1
- Mevidalen Phase 2
- Microcrystalline cellulose Phase 1
- Neflamapimod Phase 2
- Nelotanserin Phase 2
- Nilotinib Phase 2
- Rivastigmine Phase 2
- Terazosin hydrochloride Phase 1
Other linked drugs (1)
- Donepezil hydrochloride